Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -106.3%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $528962 | $3M | $5M | $24.5B | — | — | — |
| Enterprise Value | $-2228422 | $134228 | $1M | $24.5B | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — |
| P/S Ratio | 0.90 | 4.90 | 2.07 | 14288.77 | — | — | — |
| P/B Ratio | 0.00 | 0.37 | 0.77 | 6394.15 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.23 | 0.45 | 14286.95 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 12.7% | 12.7% | 72.8% | 66.2% | 58.4% | -244.0% | — |
| Operating Margin | -1250.1% | -1250.1% | -75.7% | -66.6% | -233.4% | -94928.7% | — |
| Net Profit Margin | -1306.3% | -1306.3% | -253.1% | -251.2% | -234.9% | -94889.8% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -106.3% | -106.3% | -119.1% | -173.5% | -227.6% | -367.5% | — |
| ROA | -70.5% | -70.5% | -88.1% | -121.5% | -140.7% | -229.7% | -1309.5% |
| ROIC | -142.7% | -142.7% | -82.7% | -176.4% | -899.0% | -4559.0% | — |
| ROCE | -91.5% | -91.5% | -33.7% | -43.9% | -203.8% | -367.7% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.34 | 0.34 | — | 0.06 | 0.25 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.35 | -0.60 | -0.81 | -0.77 | -0.91 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -13.48 | -13.48 | -4.46 | -58.44 | -683.77 | — | — |
Net cash position: cash ($5M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | 1.74 | 3.36 | 3.79 | 2.64 | 2.95 | 0.42 |
| Quick Ratio | 1.72 | 1.72 | 3.36 | 3.41 | 2.25 | 2.21 | 0.42 |
| Cash Ratio | 1.37 | 1.37 | 2.21 | 2.56 | 1.96 | 1.91 | 0.33 |
| Asset Turnover | — | 0.05 | 0.27 | 0.33 | 0.40 | 0.00 | — |
| Inventory Turnover | 5.42 | 5.42 | 641.95 | 1.17 | 1.39 | 0.02 | — |
| Days Sales Outstanding | — | 210.64 | 0.78 | 7.71 | 6.12 | 754.72 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $20352 | $947 | $28455 | $113439 | $112627 | $112627 |
Liquidity and clinical failure
Based on reported figures, PMGC Holdings trades at a P/S ratio of 0.86, a valuation level that appears to discount the company's legacy aesthetic revenue entirely while assigning minimal speculative value to the nascent EL-22 therapeutic program as it transitions away from its original commercial skincare operations.
The current valuation multiple suggests that the market is pricing the entity as a distressed R&D shell rather than a functional operating business. Investors should monitor whether this discount persists as the company attempts to secure clinical milestones, as the lack of a forward P/E or meaningful EBITDA suggests that traditional valuation metrics are currently disconnected from the company's fundamental reality.
According to recent quarterly filings, the company's ROIC has remained deeply negative, reaching -66.3% in 2026Q1, which indicates that the capital deployed into the business is failing to generate returns and is instead being consumed by the high fixed costs of the therapeutic development pivot.
The persistent decay in return on invested capital highlights the structural difficulty of funding a high-burn R&D program with a shrinking legacy revenue base. This trend warrants further investigation into whether management can achieve any semblance of capital efficiency before the current cash runway is exhausted by ongoing operational losses.
As reported in financial statements, the company's cash conversion cycle has shown extreme instability, fluctuating from -38 days in 2026Q1 to significantly higher levels in prior periods, which suggests that the management of payables and inventory is being disrupted by the company's rapid operational contraction.
The erratic nature of the cash conversion cycle appears to be a byproduct of the company's pivot, where legacy aesthetic inventory management is likely being deprioritized. Investors should be cautious, as the inability to maintain a predictable working capital cycle may indicate deeper operational friction that could hinder the transition to a therapeutic-focused business model.
Based on quarterly balance sheet data, the current ratio has compressed to 1.45 as of 2026Q1, reflecting a significant reduction in the company's liquidity cushion compared to the 22.38 ratio observed in 2025Q2, as cash reserves are increasingly utilized to fund ongoing research and corporate overhead.
The rapid contraction in liquidity suggests that the company's ability to withstand further operational shocks is diminishing, leaving little room for error in its clinical development timeline. This trend warrants close monitoring, as the company may be forced to seek dilutive financing if the current cash burn rate is not stabilized in the near term.
The P/S ratio is frequently misapplied to this business model, as it obscures the fact that the company's revenue is derived from a legacy aesthetic segment that is being intentionally wound down, rendering historical sales figures largely irrelevant for predicting the future value of the therapeutic pipeline.
Analysts should instead focus on the cash runway and the progress of clinical milestones, as these are the true drivers of value for a pre-revenue therapeutic entity. Relying on revenue multiples in this context may lead to a false sense of security regarding the company's commercial viability, as the current revenue base does not represent the future earning power of the EL-22 platform.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ELAB stock.
PMGC Holdings Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
PMGC Holdings Inc.'s return on equity (ROE) is -106.3%. The historical average is -198.8%.
Based on historical data, PMGC Holdings Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
PMGC Holdings Inc. has 12.7% gross margin and -1250.1% operating margin.